Pembrolizumab
- PDF / 169,302 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 92 Downloads / 186 Views
1 S
Myocarditis: case report In a retrospective review of 20 patients registered at the cancer registry of Samsung Medical Centre, who were treated for classical Hodgkin’s lymphoma (cHL) between October 2015 and December 2018, a 32-year-old woman was described, who developed myocarditis during treatment with pembrolizumab. The woman started receiving IV pembrolizumab in cycles of 3 weeks [dose not stated] for cHL. However, after 10 cycles, she reported a new, progressive dyspnoea, which developed during the previous week. Subsequent echocardiography demonstrated pericardial and pleural effusion, and a cardiac biopsy showed lymphohistiocytic infiltration with myocyte damage, compatible with lymphocytic myocarditis. The myocarditis was attributed to pembrolizumab. The woman’s therapy with pembrolizumab was therefore discontinued. She was then treated with unspecified steroids, after which she made a rapid recovery. Hur JY, et al. Immune checkpoint inhibitors in patients with pretreated HodgkinEs lymphoma: A Korean single-center, retrospective study. Blood Research 55: 85-90, No. 2, 803502189 2020. Available from: URL: http://doi.org/10.5045/br.2020.2020014
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
